Cognitive impairment in patients with metabolic syndrome. The current treatment possibilities

AIM: To study the effect of therapy with cytoflavin on cognitive function in patients with metabolic syndrome (MS). MATERIAL AND METHODS: The randomized controlled open study included 156 patients with MS. The mean age was 41.27±5.16 years. The duration of observation was 16 weeks. The main group of patients (n=78) received cytoflavin in the dose of 2 tablets 2 times a day. Patients in the control group (n=78) received basic therapy. All patients underwent neuropsychological testing at baseline, after 2 months and at the end of the study. Cognitive evoked potentials (Р300) were recorded to assess cognitive functions. The levels of plasma glucose and lipid profile were measured. RESULTS: Cytoflavin improved cognitive functions. Two months after treatment, the results of neuropsychological testing and electrophysiological study were better in the main group compared to the control group.